Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02203643 |
Recruitment Status :
Active, not recruiting
First Posted : July 30, 2014
Last Update Posted : November 30, 2023
|
Sponsor:
Mario Boccadoro
Information provided by (Responsible Party):
Mario Boccadoro, University of Turin, Italy
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | October 2016 |
Estimated Study Completion Date : | October 2033 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):